Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis

BiomX Inc. (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies, today presents new data from the company's Primary Sclerosing Cholangitis (PSC) program at the American Association for the Study of Liver Disease (AASLD) Conference in Boston.

In the study, BiomX researchers identified and characterized phages targeting pathogenic bacterial strains that are hypothesized as disease modifying in PSC, a rare progressive liver disorder with no FDA-approved treatment, affecting approximately 30,000 patients in the US. The target bacterial strains of Klebsiella pneumoniae (Kp) were isolated from the stool of patients with PSC and were previously shown to induce a Th17 inflammatory response in the liver and to disrupt the intestinal epithelial barrier in mice1. Gut permeability ("leaky gut") may lead to microbial infection of bile, resulting in inflammation and fibrosis within the liver of PSC patients, suggesting that Kp may serve as a therapeutic target for phage therapy.

In the study presented today, cohort analyses based on metagenomic sequencing of stool samples collected from over 350 PSC patients and healthy controls from three countries, revealed that the prevalence and abundance of the target bacteria is higher in PSC patients compared to healthy controls, and that abundance is associated with disease severity (positively correlated with advanced liver fibrosis) and longer disease duration. BiomX researchers further conducted phage hunting efforts resulting in over 20 phages, from which over a 100 combinations (cocktails) were designed and compared for their ability to effectively eradicate Kp in vitro. This process allowed for the selection of a phage cocktail that was able to substantially reduce bacterial burden of the target Kp strains in vivo by over 3 orders of magnitude, while also efficiently limiting the emergence of mutant bacteria with resistance to the cocktail.

"We believe that phage therapy holds promise for the treatment of patients with PSC, who are in dire need of novel therapeutic approaches to this disease for which there are presently no satisfactory treatments." said Jonathan Solomon, BiomX's CEO. "We are encouraged by these results and are committed to continue moving this program forward to clinical trials, planned for the first half of 2021."

PSC is characterized by inflammation and fibrosis within the bile ducts. Scarring of the liver, or cirrhosis, eventually develops and many patients ultimately require a liver transplant. Recent studies suggest linkage between the microbiome and PSC, especially given that compromises in the intestinal barrier caused by alterations in the microbiome may expose the bile ducts and liver to altered levels of bacteria and their products, which may trigger aberrant inflammatory responses.

Safe Harbor Language
This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management's current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. You should review additional disclosures we make in our filings with the Securities and Exchange Commission (the "SEC"), which are available on the SEC's website at www.sec.gov.

About BiomX
BiomX is a clinical-stage company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC, and cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

1 Nakamoto et al. Nature Microbiology, 2019

These press releases may also interest you

at 10:00
White Knight Press has just released Photographer's Guide to the Nikon Coolpix P950, a full-color, detailed guide book covering the menus, features, controls, and operation of the Nikon Coolpix P950 superzoom camera. This book, by Alexander S. White,...

at 08:05
Incyte today announced the first presentation of Phase 3 data for ruxolitinib cream in atopic dermatitis at the Revolutionizing Atopic Dermatitis Virtual Symposium. The Phase 3 TRuE-AD program, which includes the TRuE-AD1 and TRuE-AD2 studies, is...

at 08:00
As people in America and around the world continue to practice safety within their homes; in an effort to control the spread of this virus we present to you a Def Comedy Jam in support of communities in need during this COVID-19 Public Health Crisis,...

at 07:00
Plataine, a leading provider of Industrial IoT (IIoT) and AI-based software for advanced manufacturing optimization, is excited to announce that it joined the membership network of The National Composites Centre (NCC), the UK research center...

4 avr 2020
Womply, a software and API company serving small businesses and app developers, today announced that it is helping American small businesses get faster access to Paycheck Protection Program loans as a verified loan agent for multiple SBA 7(a)...

4 avr 2020
Ex-Formula 1 stars Rubens Barrichello and Jan Magnussen plus esports racer Kevin Siggy were the big winners in today's Legends Trophy esports races and The Race All-Star Cup - Fully Charged by ROKiT Phones. The...

News published on 12 november 2019 at 07:35 and distributed by: